CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

CVS Health Corp. closed $34.74 short of its 52-week high ($80.75), which the company reached on March 28th.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $241,558, and 4 are calls, for a total ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

CVS Health CVS shareholders are experiencing a rough period as the stock continues to face significant downward pressure. Recent reports about the company's strategic restructuring plans have ...

In a report released today, Charles Rhyee from TD Cowen maintained a Hold rating on CVS Health (CVS – Research Report), with a price target of ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

CVS Health Corp. shares dipped below $50 on Thursday ... Separately, PBMs are being sued by the Federal Trade Commission. The industry is pushing back, saying the lawsuits are without merit ...

In September, the Federal Trade Commission sued the PBMs owned by CVS, UnitedHealth and Cigna, alleging they artificially raised prices on insulin drugs. CVS is a PBM through its CVS Caremark ...

Innovative approach uses a transparent formula built on the drug acquisition cost, a set markup, and a fee to reflect the quality of pharmacy services provided New reimbursement model supports ...